MBX Biosciences Inc

MBX is in a Stage 4 decline following support failure through key EMAs, establishing a medium-term bearish bias. Short-term price remains below declining EMAs with no exhaustion pattern, aligning with a momentum strategy that favors selling into rallies around the broken support cluster near the 9/20/50 EMA zone. The long-term uptrend stays intact above the rising 200-day SMA.

• ↑Promising Phase 3 trial for canvuparatide in Q3 2026 after strong one-year data.
• ↑$418.6M in cash and securities funds operations into 2029, reducing near-term dilution.
• ↓Q2 2026 net loss of $37.1M ($0.78/share) vs $19.4M prior year, missing consensus by $0.10.